Esperion Therapeutics ESPR Accrued clinical development costs
Accrued clinical development costs at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept espr:AccruedClinicalDevelopmentCostsCurrent.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's accrued clinical development costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's accrued clinical development costs?
- Esperion Therapeutics (ESPR) reported accrued clinical development costs of $2.68M in Q1 2026.
- How has Esperion Therapeutics's accrued clinical development costs changed year-over-year?
- Esperion Therapeutics's accrued clinical development costs decreased by 62.1% year-over-year, from $7.07M to $2.68M.
- What is the long-term trend for Esperion Therapeutics's accrued clinical development costs?
- Over 5 years (2020 to 2025), Esperion Therapeutics's accrued clinical development costs has grown at a -11.7% compound annual growth rate (CAGR), from $7.66M to $4.12M.
- What does accrued clinical development costs mean?
- This captures expenses incurred for clinical trials and research activities that have been performed but not yet invoiced or paid by the company. It represents a short-term liability that reflects the actual pace of research and development operations. Tracking this provides insight into the true operational burn rate associated with the clinical pipeline.